ArticleBioinformation2026
Triamcinolone acetate and triamcinolone-isotretinoin efficacy in oral lichen planus management: Original clinical study.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral lichen planus (OLP) is a long-term inflammatory mucocutaneous disease that has the potential of malignant transformation. Hence, it requires effective long-term therapy. It was a randomized controlled, double-blind trial comparing triamcinolone acetonide 0.1 per cent oral paste (TA) to TA once daily with oral isotretinoin 10mg daily (TA+ISO) in 70 cases (biopsy-established) of OLP of more than 12 weeks duration. The TA+ISO group showed better clinical outcomes as the means of Thongprasom scores reduced in the TA group (p<0.001). TA+ISO showed more pain reduction (VAS) at 12 weeks (p<0.001), improved Histopathological (74.3) TA+ISO (p=0.006) and reduced Lesion size (p<0.001). TA in combination with isotretinoin is very useful as combination therapy in OLP and clinical and histopathological results are improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.